SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud by Derma Sciences, Inc. and Certain Officers and Directors

NEW YORK--()--Levi & Korsinsky, LLP announces that it has commenced an investigation of Derma Sciences, Inc. (“Derma Sciences” or the “Company”) (NASDAQ:DSCI) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On November 12, 2015, Derma Sciences announced the termination of its Phase 3 clinical trials with aclerastide for diabetic foot ulcer healing after a data monitoring committee issued a futility determination. Upon this news, shares of Derma Sciences were down 27.59% on intraday trading. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/derma-sciences-dsci

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com

Release Summary

Levi & Korsinsky, LLP announces that it has commenced an investigation of Derma Sciences, Inc. concerning possible violations of federal securities laws by the Company

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com